Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETERMINE Arm 04: Trastuzumab + Pertuzumab in HER2-Altered Rare Cancers
NCT05786716Phase 3Recruiting
- Sponsor
- Cancer Research UK
- Start
- Mar 2023
- Primary completion
- Oct 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab and pertuzumab in solid tumor and haematological malignancy, sponsored by Cancer Research UK. Primary endpoints: Objective Response at 24 weeks and Durable Clinical Benefit at 24 weeks. Started Mar 2023; status: recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
solid tumorhaematological malignancy
Beyond the preview
Go deeper on NCT05786716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786716.